Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.

International journal of molecular sciences - 21 Nov 2023

Carrasco Raquel, Ingelmo-Torres Mercedes, Trullas Ramón, Roldán Fiorella L, Rodríguez-Carunchio Leonardo, Juez Lourdes, Sureda Joan, Alcaraz Antonio, Mengual Lourdes, Izquierdo Laura

Abstract excerpt

Circulating tumor DNA (ctDNA) has recently emerged as a real-time prognostic and predictive biomarker for monitoring cancer patients. Here, we aimed to ascertain whether tumor-agnostic ctDNA testing would be a feasible strategy to monitor disease progression and therapeutic response in muscle-invasive bladder cancer (MIBC) patients after radical cystectomy (RC). Forty-two MIBC patients who underwent RC were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell-Free Nucleic Acids

Share to Circulating Tumor DNA

Share to DNA, Neoplasm

Share to Muscles

Share to Mutation

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 38068899
DOI: 10.3390/ijms242316578
PMCID: PMC10706140

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor-Agnostic Circulating Tumor DNA Testing for Monitoring Muscle-Invasive Bladder Cancer.PMID 38068899Read ↗

Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder CancerSemantic proximity Read ↗

Real-World Experience with a Commercial Circulating Tumor DNA Assay in Non–muscle-invasive Bladder CancerSemantic proximity Read ↗

Prognostic implication of TERT promoter mutation and circulating tumor cells in muscle-invasive bladder cancer.Semantic proximity Read ↗

Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer.Semantic proximity Read ↗

The evolving landscape and clinical utility of circulating tumor DNA across the spectrum of urothelial carcinoma: A systematic review and framework for clinical integration.Semantic proximity Read ↗

Whole genome mutational analysis for tumor-informed ctDNA based MRD surveillance, treatment monitoring and biological characterization of urothelial carcinomaSemantic proximity Read ↗

Integrated Plasma and Urinary Cell-free DNA Profiling Enables Noninvasive Molecular Detection from Ta to T4 Bladder CancerSemantic proximity Read ↗

Circulating-tumor DNA as an early detection and diagnostic tool.Semantic proximity Read ↗

Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-upSemantic proximity Read ↗

Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-upSemantic proximity Read ↗

Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.Semantic proximity Read ↗

TERT Promoter Mutations as Simple and Non-Invasive Urinary Biomarkers for the Detection of Urothelial Bladder Cancer in a High-Risk Region.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.